E. Zintzaras, M. Voulgarelis, and H. Moutsopoulos, The Risk of Lymphoma Development in Autoimmune Diseases, Archives of Internal Medicine, vol.165, issue.20, pp.2337-2381, 2005.
DOI : 10.1001/archinte.165.20.2337

K. Smedby, H. Hjalgrim, J. Askling, E. Chang, H. Gregersen et al., Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype, JNCI Journal of the National Cancer Institute, vol.98, issue.1, pp.51-60, 2006.
DOI : 10.1093/jnci/djj004

O. Landgren, E. Engels, R. Pfeiffer, G. Gridley, L. Mellemkjaer et al., Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case-Control Study in Scandinavia, JNCI Journal of the National Cancer Institute, vol.98, issue.18, pp.1321-1351, 2006.
DOI : 10.1093/jnci/djj361

E. Baecklund, A. Iliadou, J. Askling, A. Ekbom, C. Backlin et al., Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis & Rheumatism, vol.36, issue.3, pp.692-701, 2006.
DOI : 10.1002/art.21675

A. Kandiel, A. Fraser, B. Korelitz, C. Brensinger, and J. Lewis, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, vol.54, issue.8, pp.1121-1126, 2005.
DOI : 10.1136/gut.2004.049460

O. Kamel, M. Van-de-rijn, L. Weiss, D. Zoppo, G. Hench et al., Reversible Lymphomas Associated with Epstein-Barr Virus Occurring during Methotrexate Therapy for Rheumatoid Arthritis and Dermatomyositis, New England Journal of Medicine, vol.328, issue.18, pp.1317-1338, 1993.
DOI : 10.1056/NEJM199305063281806

F. Wolfe and K. Michaud, The effect of methotrexate and anti???tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation, Arthritis & Rheumatism, vol.52, issue.5, pp.1433-1442, 2007.
DOI : 10.1002/art.22579

X. Mariette, D. Cazals-hatem, J. Warszawki, F. Liote, N. Balandraud et al., Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France, Blood, vol.99, issue.11, pp.3909-3924, 2002.
DOI : 10.1182/blood.V99.11.3909

J. Askling, E. Baecklund, F. Granath, P. Geborek, M. Fored et al., Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register, Ann Rheum Dis, vol.68, issue.5, 2008.

S. Setoguchi, D. Solomon, M. Weinblatt, J. Katz, J. Avorn et al., Tumor necrosis factor ?? antagonist use and cancer in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.14, issue.9, pp.2757-64, 2006.
DOI : 10.1002/art.22056

F. Wolfe and K. Michaud, Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis & Rheumatism, vol.359, issue.6, pp.1740-51, 2004.
DOI : 10.1002/art.20311

F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille et al., Risk of tuberculosis higher with monoclonal-antibody than with soluble-receptor anti-TNF therapy in the 3-year prospective French RATIO registry, Arthritis Rheum, 2009.

F. Tubach, D. Salmon-ceron, P. Ravaud, and M. X. , The RATIO observatory: French registry of??opportunistic infections, severe bacterial infections, and??lymphomas complicating anti-TnF?? therapy, Joint Bone Spine, vol.72, issue.6, p.25, 2005.
DOI : 10.1016/j.jbspin.2005.10.004

E. Von-elm, D. Altman, M. Egger, S. Pocock, P. Gotzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement, Epidemiology, vol.18, issue.6, p.296, 2007.
DOI : 10.1097/EDE.0b013e3181577654

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006.
DOI : 10.1001/jama.295.19.2275

T. Bongartz, F. Warren, D. Mines, E. Matteson, K. Abrams et al., Etanercept therapy in rheumatoid arthritis and the risk of malignancies, Ann Rheum Dis, vol.67, p.12, 2008.

A. Mackey, L. Green, L. Liang, P. Dinndorf, and M. Avigan, Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.265-272, 2007.
DOI : 10.1097/MPG.0b013e31802f6424

E. Agency, Committee for medicinal products for human use, 2008.

S. Park, C. Kim, J. Kim, and J. Choe, Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment, Rheumatology International, vol.311, issue.5, pp.475-482, 2008.
DOI : 10.1007/s00296-007-0467-6

R. Thonhofer, M. Gaugg, M. Kriessmayr, H. Neumann, and L. Erlacher, Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment, Annals of the Rheumatic Diseases, vol.64, issue.7, pp.1098-1107, 2005.
DOI : 10.1136/ard.2004.026252

F. Baran-marszak, C. Laguillier, I. Youlyouz, J. Feuillard, X. Mariette et al., Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein???Barr virus, Cytokine, vol.33, issue.6, pp.337-382, 2006.
DOI : 10.1016/j.cyto.2006.03.005

URL : https://hal.archives-ouvertes.fr/hal-00451195

B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X. Song et al., Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists, Journal of Pharmacology and Experimental Therapeutics, vol.301, issue.2, pp.418-444, 2002.
DOI : 10.1124/jpet.301.2.418